

FRESENIUS KABI PHARMACEUTICALS HOLDING, INC.  
CONSOLIDATED RESULTS OF OPERATIONS

(Unaudited, in thousands)

	Three months Ending September 30, 2008	July 2 through September 30, 2008	July 1 through September 9 2008
	Combined	(Successor)	(Predecessor)
Revenues			
Critical care	\$ 129,614	\$ 29,606	\$100,008
Anti-infective	53,815	13,792	40,023
Oncology	11,463	4,294	7,169
Contract manufacturing and other	2,988	388	2,600
Total revenue	197,880	48,080	149,800
Cost of sales	90,642	22,190	68,452
Amortization of inventory step-up	12,588	12,588	-
Gross profit	94,650	13,302	81,348
Percent to total revenue	47.8%	27.7%	54.3%
Research and development	11,036	2,066	8,970
Selling, general and administrative	23,813	5,508	18,305
Amortization of in-process R&D	252,000	252,000	-
Amortization of merger related intangibles	5,960	3,389	2,571
Separation costs	235	-	235
Merger related costs	44,799	1,188	43,611
Total operating expenses	337,843	264,151	73,692
Percent to total revenue	170.7%	549.4%	49.2%
(Loss) income from operations	(243,193)	(250,849)	7,656
Percent to total revenue	-122.9%	-521.7%	5.1%
Interest income and other	215	(16)	231
Gain on contingent value right	52,241	52,241	-
Interest expense	(42,363)	(27,866)	(14,497)
(Loss) income from continuing operations before income taxes	(233,100)	(226,490)	(6,610)
Income tax (benefit) expense	8,761	(8,135)	16,896
Net (loss) income from continuing operations	\$(241,861)	\$(218,355)	\$(23,506)
Net loss from discontinued operations, net of taxes	-	-	-
Net (loss) income	\$(241,861)	\$(218,355)	\$(23,506)
Selected ratios as a percentage of total net revenues:			
Research and development	5.6%	4.3%	6.0%

Selling, general and administrative	12.0%	11.5%	12.2%
-------------------------------------	-------	-------	-------

	Three months	Change	
	Ending	Favorable	
	September 30,	(Unfavorable)	
	2007	\$	%
	(Predecessor)		
Revenues			
Critical care	\$ 91,584	\$ 38,030	42%
Anti-infective	43,032	10,783	25%
Oncology	14,073	(2,610)	-19%
Contract manufacturing and other	4,490	(1,502)	-33%
Total revenue	153,179	44,701	29%
Cost of sales	85,055	5,587	7%
Amortization of inventory step-up	-	12,588	-
Gross profit	68,124	26,526	39%
Percent to total revenue	44.5%		
Research and development	11,351	(315)	-3%
Selling, general and administrative	22,061	1,752	8%
Amortization of in-process R&D	-	252,000	-
Amortization of merger related intangibles	3,856	2,104	55%
Separation costs	352	(117)	-33%
Merger related costs	-	44,799	-
Total operating expenses	37,620	300,223	-
Percent to total revenue	24.6%		
(Loss) income from operations	30,504	(273,697)	-
Percent to total revenue	19.9%		
Interest income and other	886	(671)	-76%
Gain on contingent value right	-	52,241	
Interest expense	(3,831)	(38,532)	-
(Loss) income from continuing operations before income taxes	27,559	(260,659)	-
Income tax (benefit) expense	13,449	(4,688)	-35%
Net (loss) income from continuing operations	\$ 14,110	\$(255,971)	-
Net loss from discontinued operations, net of taxes	(22,495)	22,495	-
Net (loss) income	\$ (8,385)	\$(233,476)	-
Selected ratios as a percentage of total net revenues:			
Research and development	7.4%		
Selling, general and administrative	14.4%		